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nicomorphine (Vilan) with its metabolites and 
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Abstract. The kinetics of 20 mg nicomorphine intramuscularly were described in 8 patients under
combined general and epidural anesthesia. The half-life of nicomorphine was 0.32 ± 0.20 h (mean ± 
SD) and is governed by the absorption- rather than the elimination rate. The half-life of 6-mononico-
tinoylmorphine (0.39 ± 0.09 h) was identical to that of the parent compound (p = 0.29), suggesting it
is directly related to the absorption rate of nicomorphine. Morphine had a half-life of 1.38 ± 0.31 h. 
Morphine is subsequently metabolized into morphine-3-glucuronide and morphine-6-glucuronide. 
The half-life of these 2 glucuronide conjugates was about 2.6 h (p = 0.07). A glucuronide conjugate 
of 6-mononicotinoylmorphine was not detected. In urine only morphine and its glucuronides are 
found, with renal clearance values of 214 mLmin-1 for morphine and 132 ml.min-1 for the glucu­
ronides. The bioavailability of this pharmaceutical formulation after intramuscular administration 
equals that of intravenous administration in surgical patients (at the same dose).
Key words: pharmacokinetics: nicomorphine -  6-mononicotinoylmorphine -  morphine -  glucu­
ronides -  bioavailability
Introduction
Nicomorphine (3,6-dinicotinoylmorphine, DNM) has 
been introduced as an opioid analgesic both for systemic 
and perispinal use. Nicomorphine is considered to be a 
"prodrug" which exerts its analgesic effects through 1 or 
several of its metabolites [Dirksen et al. 1987, Pinckaers et 
al. 1982]. The 2 nicotinoyl ester groups increase the lipid- 
solubility and permit chemical and enzymatic hydrolysis 
into 3- or 6-mononicotinoylmorphine and then into mor­
phine. Morphine is subsequently glucuronidated at the C3- 
and C6-position, yielding morphine-3-glucuronide and 
morphine-6-glucuronide.
In order to measure nicomorphine and its metabolites 
we developed a sensitive method of analysis by means of 
HPLC with electrochemical and UV detection [Koopman- 
Kimenai et al. 1987] and described the pharmacokinetic 
behavior of nicomorphine and its unconjugated metabo­
lites 6-mononicotinoylmorphine (6MNM) and morphine 
(M) [Koopman-Kimenai et al. 1991a]. The serum concen-
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tration-time course of nicomorphine and its metabolites 
depend on the route of administration as shown earlier for 
the unconjugated compounds [Koopman-Kimenai et al.
1991a, 1991b, 1993].
In this study we investigated the pharmacokinetics of 
nicomorphine with its metabolites and their glucuronide 
conjugates inpatients after intramuscular administration of 
20 mg Vilan. The results were compared to those obtained 
with 20 mg intravenously administered Vilan [Koopman- 
Kimenai et al. 1993] to assess the bioavailability of Vilan 
in a comparable group of surgical patients.
Patients and methods
Patients
The study was carried out in n = 8 AS A I-II patients 
(healthy patients, according to the classification of the 
Association of American Anesthesiologists), aged 25 -  50
years, mean 37 ± 9 y (± SD), with normal body weights:
62 ± 6 kg and with normal body lengths: 166 ± 6 cm. All 
patients were scheduled to undergo gynecological elective 
abdominal surgery. Approval was given by the local Ethics 
Committee and informed consent obtained from each pa­
tient. The patients studied and the method of anesthesia are
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extensively described in our previous article [Koopman- 
Kimenai 1991a]. Excluded were patients with liver or 
kidney dysfunction, known allergic reactions, use of opi­
ates or opiate antagonists, or an expected blood loss greater 
than 500 ml during the surgical procedure.
The patients recieved 20 mg nicomorphine (Vilan) 
intramuscularly in the deltoid muscle (1.5 cm deep). The 
Vilan injections were given during maintenance of anes­
thesia after the start of surgery when the patient’s condition 
was stable.
Drugs
Nicomorphine (DNM), 3-mononicotinoylmorphine 
(3MNM), 6-mononicotinoylmorphine (6MNM), mor­
phine (M), and Vilan (nicomorphine hydrochoride) were 
obtained from Nourypharma (Oss, the Netherlands). Mor- 
phine-3-glucuronide (M3G) and morphine-6-glucuronide 
(M6G) were obtained from Sigma (St. Louis, MO, USA).
Sampling
Blood samples of 5 ml were taken just before and at 
regular time intervals during and after anesthesia: 1, 2, 3, 
4, 5, 6, 7, 8, 10, 15, 20, 30, 45, 60,90, 120, 240, 360,480
min, 12 h, and 24 h after the administration of nicomor­
phine. The samples were centrifuged at 3,000 rpm and the 
serum was stored at -20° C until analysis.
Urine samples were taken from the urine catheter in 
the intervals: 0 -  0.5 h, 0.5 -  1.0 h, 3 -  2 h, 2 -  4 h, 4 -  6 
h, 6 -  8 h, 8 -  12 h, 12 -  18 h, 18 -  24 h, 24 -  36 h, and 36
-  48 h. The total volume was measured and a sample (in 
duplo) was stored at -20° C until analysis.
Sample preparation
DNM, 6MNM and M were extracted as previously 
published [Koopman-Kimenai et al. 1987]. Both morphine 
glucuronides were quantified simultaneously with mor­
phine under slightly modified conditions. The solid phase 
extraction of 0.6 ml serum was carried out on 1 ml cyclohe- 
xyl cartridges (C6H6, Baker, Cat. No. 7212-01). It was 
washed with 2 ml of 50 mM diammoniumsulphate (pH 9.3) 
and eluted with 0.5 ml 0,01 M KH2PO4 buffer pH = 2.1 
containing 11 % acetonitrile. This is a modification of the 
method described by Svensson et al. [1986].
Urine samples were treated in the same way because 
only morphine and its glucuronides could be detected.
Because of the higher concentrations 100 jil urine were 
extracted and the column rinsed with 5 column volumes 
ammoniumsulphate buffer (50 mM) before the elution with 
1 ml 0.01 M KH2PO4 buffer pH = 2.1 containing 1 1% 
acetonitrile could be carried out.
HPLC conditions
Nicomorphine and its unconjugated metabolites 
3MNM, 6MNM, and M were determined by means of 
HPLC as previously described [Koopman-Kimenai et al.
1987].
Morphine and its glucuronides were separated on a 
Cp-Sper C8 column (Chrompack, Bergen op Zoom, the 
Netherlands). The mobile phase was a 0.01 M KH2PO4 
buffer pH = 2.1 containing 11% acetonitrile and 0.4 g.l-1 
heptane sulfonic acid (Janssen Chimica, Beerse, Belgium). 
At a flowrate of 2 ml.min"1, M3G was detected with a 
UV-detector at wavelength 210 nm (Spectroflow 773, Sep­
arations, HI-Ambacht, the Netherlands) at a retention time 
of 2.3 min. Both M6G and M are electrochemically active 
and were quantified using an ESA electrochemical detector 
(ESA, Kratos, Rotterdam, the Netherlands) equipped with 
an analytical cell (Model 5010). The detector 1 potential 
was 0.3 V in order to minimize interfering peaks and the 
detector 2 potential was set at 0.4 V. The retention times 
were 2.8 min and 3.5 min for M6G and M, respectively.
Recovery and reproducibility
Calibration curve: The calibration curves were pre­
pared by adding a variable quantity of stock solution to 
blank serum or urine. The calibration samples for electro­
chemical detection and UV detection were prepared separ­
ately. The calibration graphs were linear for M in concen­
trations ranging from 5 -  300 ng.ml-1 (r = 0.9975), for 
6MNM in concentrations ranging from 2 - 3 0 0  ng.ml-1 (r 
= 0.9915), for 3MNM in concentrations ranging from 1 0 -  
300 ng.ml” 1 (r = 0.9810) and for DNM concentrations 
ranging from 9 -  800 ng.ml-1 (r = 0.9965). After extraction
of patient samples, the sample has a volume o f200 p i This 
enables injection of the same sample simultaneously on
both HPLC systems: 20 |xl for electrochemical detection
and 100 jLxl for UV detection. The quantitation limit in 
serum for M is 5 ng.ml-1 and 6MNM is 2 ng.ml“1, for 
3MNM 10 ng.ml-1, and 9 ng.ml-1 for DNM.
For the measurement of M3G, M6G, and M, the 
calibration samples contained all 3 compounds. In serum: 
all calibration graphs were linear. For M3G the concentra­
tions ranged from 2 5 -5 8 0  ng.ml“ 1 (r = 0.9992). For M6G 
the concentrations ranged from 5 -  100 ng.ml"'1 (r = 
0.9982) and for M this range was from 5 - 9 0  ng.ml“ 1 (r = 
0.9963). The quantitation limit is 25 ng.ml“"1 for M3G and 
5 ng.ml-1 for M6G and M. The limit of quantitation was 
defined as 3 times the noise level, but dealing with patient 
samples, the nature and amount of comedication and en­
dogenous compounds present, sometimes strongly in­
fluence the minimum quantity that can be measured.
In urine also all calibration curves were linear. The 
ranges and correlation coefficients are as follows: For
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M3G: 1 -  20 n g . m H  (r =  0.9988), fo r  M6G: 0.2 -  10 
ILig.ml“ 1 (r = 0.9997) an d  fo r  M 0.2 -  10 | i g . m H  (r = 
0.9996). The quan tita tion  l im it  is 1 ¡xg.ml" 1 fo r  M3G and
0.2 ¡ag.ml"'1 for M6G and M.
The reproducibility was approximately 5% for the 
concentration ranges of all the above mentioned com­
pounds.
The recoveries for the cyanopropyl extraction proce­
dure for DNM, 6MNM, and 3MNM, and M were 69%, 
96%, 91%, and 87%, respectively. The percentages of 
recovery for the cyclohexyl extraction procedure for M3G, 
M6G, and M were 96%, 97%, and 97%, respectively.
-  the parent compound,
-  the active metabolites (6MNM + M + M6G),
-  all measured compounds (DNM + 6MNM + M + 
M3G + M6G) after intramuscular administration in 
comparison to the intravenous administration (of the 
same dose nicomorphine).
Statistics
P values were calculated using analysis of variance 
according to standard procedures. Statistical difference is 
defined at p < 0.05.
Procedure for the detection o f glucuronides Results
Deglucuronidation was carried out with P-glucuroni Figure 1 shows representative serum concentration-
dase type H-2 from Helix pomatia (G-0876, Sigma, St time curves of nicomorphine and its metabolites in a patient 
Louis, USA). A sample of 100 p.1 was mixed with 25 p.1 (No. 6) after an i.m. dose of 20 mg nicomorphine. Nico-
B-glucuronidase type H-2 and 125 jal buffer (0.2 M so- morphine (DNM) was detectable in serum during 1 hour
and was eliminated with a half-life of 0.29 h. Its apparent
half-life is governed by its rate of absorption and in the 
different patients it varied between 0.11 and 0.71 h (Table 
1). 6-Nicotinoylmorphine (6MNM) was almost instanta­
neously formed, at tmax (0.16 h) it reached a Cmax of 55 
ng.ml" 1 and it was eliminated with a ti/2 of 0.30 h. Mor-
diumacetate pH = 5.0). The reaction was carried out over­
night and was stopped by addition of 800 jwl 500 mM 
diammoniumsulphate buffer pH = 9.3, followed immedi­
ately by the extraction procedure. Both morphine glucu­
ronides are commercially available, and calibration 
samples, with a known amount of glucuronides, were 
subjected to this reaction. Under these conditions the glu­
curonides completely disappeared from the chromatogram 
while there was an equal molar increase in morphine con­
centration.
Pharmacokinetics
All pharmacokinetic calculations were carried out 
using the computer package MW/Pharm obtained from 
Mediware (Groningen, the Netherlands) [Proost and 
Meijer 1992]. This is a nonlinear curvefitting program 
based on the least-square method. All data were fitted in a 
model implying an extravascular administration with a lag 
time and a 1-compartment elimination profile. The coeffi­
cient of determination (r2) shows the fit between calculated 
curve and the serum-time data. The area under the serum 
concentration-time curve (AUCo-^) was calculated from 
the data of the fitted curve and extrapolated to infinite time 
(all rest areas were below 25%). Total body clearance 
(CLjm) was calculated as Dose/AUCo-00. The maximum 
serum concentration Cmax (ng.ml'"1) occurs at tmax (h) in 
the fitted curve.
The renal clearance (CLr) of all metabolites present 
in the urine was calculated as excretion rate (i^g.min“1)
divided by the serum concentration (jxg.ml“1) at the mid­
point of the urine collection interval.
Bioavailability is defined in 3 levels as the percentage 
of the AUCo-oo of:
1
serum conc. ug/ml
20 mg Nicomorphine i.m.
,cP°'-o^
M-3-gluc 
t1/2 3.7 h
0 . 0 0 1
\ t1/2 0.3 h
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M
t1/2 1.4 h
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Fig. 7 The serum concentrati on-time curves of nicomorphine (DNM) 
and its metabolites 6-mononicotinoylmorphine (6MNM), morphine (M)t 
morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) in a 
patient after an i.m. dose of 20 mg nicomorphine.
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Table 1 Pharmacokinetic parameters of nicomorphine and its metabolites after an intramuscular dose of 20 mg Vilan
Patient
Parameter 1 2 3 4 5 6 7 8 mean (± SD)
Nicomorphine
Cmax (ng*ml )^ 74 73 39 104 179 100 102 50 90 ±43
tmax (h) 0.18 0.06 0.26 0.07 0.06 0.16 0.15 0.20 0.15 ±0.09
AUCo~oo Olg.h.r1) 90 58 31 31 39 61 54 42 50 ±20
AUCo_oo ((iM.h.f1) 0.18 0.12 0.06 0.06 0.08 0.12 0.11 0.08 0.10 ±0.04
CLim (1/h) 223 346 636 638 509 328 370 520 446 ± 152
ti/2 (h) 0.71 0.51 0.32 0.16 0.11 0.29 0.24 0,41 0.32 ±0.20
X 0.926 0.892 0.972 0.916 0.988 0.981 0.985 0,834
6-mononicotinoylmorphine 
Cmax (ng.ml-1) 34 38 46 60 95 55 53 33 52 ±20
tmax (h) 0.22 0.15 0.35 0.11 0.09 0.29 0.17 0.17 0.19 ±0.09
AUCo-oo (lig.h.r1) 30 30 50 45 40 47 44 48 41 ±7
AUCo-oo (liM .hr1) 0.08 0.08 0.13 0.12 0.10 0.12 0.11 0.12 0.11 rt 0.02
ti/2 (h) 0.42 0.44 0.44 0.44 0.23 0.30 0.45 0.89 0.39 ±0.09
2r 0.933 0.976 0.966 0.968 0.983 0.984 0.979 0.802
Morphine 
Cmax (ng.ml-1) 35 33 39 47 50 36 36 39 39 ± 6
tmax (h) 0.66 0,71 1.25 0.74 0.47 0.74 0.48 0,90 0.74 ± 0.25
AUCo~oo(ng.h.l 59 121 142 127 116 102 85 96 106 ± 26
AUCo~w ( i^M.h.I-1) 0.21 0.42 0.50 0.45 0,41 0.36 0.30 0,34 0.37 ± 0.09
ti/2 (h) 0.52 2.03 1.34 1.24 1.25 1,43 1.37 1.06 1.38 ±0.31
r2 0.904 0.885 0.949 0.995 0.988 0.986 0,977 0.980
CLr (ml.min“1) 186 170 264 221 181 234 il IM 245 214 ± 36
% in urine 9.6 10.0 10.4 14.5 8.7 11.1 — 10.1 10.6 ±1.9
Morphine-3-glucuronide 
Cmax (ng.ml ^ 246 333 219 244 280 194 199 184 236 ± 50
tmax (h) 1.53 1.20 2.58 1.35 1.32 1,32 1.17 2.14 1.57 ±0.51
AUCo-oo (lig.h.r1) 1124 2136 1563 1909 1304 1283 1228 945 1465 ±450
AUCo-oo ftLM.hr1) 2.43 4.62 3.38 4.13 2.82 2.78 2.66 2.05 3.11 ±0.88
ti/2 (h) 1.92 3.52 2.87 4.38 2.21 3.66 3.52 2.42 3.06 ±0.84
r2 0.994 0.905 0.994 0.899 0.987 0.991 0.990 0.996
CLr (ml.min-1) 113 108 239 76 139 108 — 84 124 ±55
% in urine 47.1 47.7 40.7 35.8 43.1 63.3 — 41.6 45.6 ±8.8
Morphine-6-glucuronide 
Cjnax (ng.ml ^ 35 42 25 26 40 41 40 24 34± 8
tmax (h) 1.57 1.86 2.44 1.72 1.59 1.42 1.03 2.33 1.75 ±0.46
AUCo-«, ftig .h r1) 154 207 194 128 182 204 214 115 175 ±38
AUCo-~ (liM.h.l“1) 0.33 0.45 0.42 0.28 0.39 0,44 0.46 0.25 0.38 ±0.08
ti/2 (h) 1.57 1.79 3.65 2.08 1.90 2.54 3.25 1.23 2.25 ±0.84
r2 0.877 0.980 0.959 0.980 0.996 0.980 0.989 0.946
CLr (ml.min"1) 136 100 229 117 90 144 — 155 139 ±46
% in urine 7.5 6.6 7.4 5.0 5.7 7.6 5.5 6.5 ±1.1
Cmax = maximum serum concentration in the fitted curve; tmax = time at which Cmax occurs in the fitted curve; AUCo-«*, Q ig .h .r1 or j iM .h .r1) = area 
under the serum concentration time curve as was calculated from the data of the flttedcurve and extrapolated to infinite time; t \n = half-life of elimination; 
CLim = total body clearance after i.m. administration; C L r = renal clearance; % in urine = total amount recovered in the urine as percentage of the dose 
of the administered compound (% molar), -  = no urines available
phine was present in the first serum sample, reached a C m ax 
of 36 ng.ml-1 at tmax of 0.74 h and was eliminated with a 
ti/2 of 1.4 h. Morphine-3-glue uronide and morphine-6-glu- 
curonide appeared simultanously in the serum and reached 
their maximum concentration after 1.37 h. They were 
eliminated with almost identical half-lives of 3.66 h (M3G) 
and 2.54 h (M6G).
Figure 2 shows renal excretion rate-time profiles of 
nicomorphine and its metabolites in the same patient of 
Figure 1. Morphine-3-glucuronide was the main metabo­
lite in urine. Of the dose administered 63.3% appeared in 
the urine as M3G, 11.1% as M and 7 *6% as M6G.
Table 1 summarizes the pharmacokinetic parameters 
of nicomorphine and its metabolites in the 8 patients. The
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Table 2 Bioavailability and AUCo^» after i.m. and i.v. administration of 
2 0  mg nicomorphine in surgical patients
AUCo-~(nM.h.r') AUCo-~(nM.h.r')
Intravenous* Intramuscular Bio-
Compound n = 5 n = 8 availability
DNM 0.06 ±0.02 0.10 ±0.04 156%
6 MNM 0.07 ± 0.01 0 . 1 1  ±0.02
M 0.40 ±0.11 0.37 ±0.09
M3 G 3.81 ±0.79 3.11 ±0.88
M6G 0.44 ±0.13 0.38 ±0.08
Active compounds: 0.91 ±0.17 0 .8 6 ±  0.12 95%
(6MNM + M + M6G)
Total 4.78 + 0.81 4.07 ± 0 .89 85%
*Taken from [Koopman-Kimenai et al. 1994]
ti/2 of nicomorphine (0.32 ± 0.20 h) and of 6-mononicoti- 
noylmorphine (0.39 ± 0.09 h) were similar (p = 0.29). The
11/2 of morphine (1.38 ± 0.31 h) differed significantly from 
those of M3G and M6G (p < 0.01). The tj/2 of M3G (3.06 
± 0.84 h) and M6G (2.25 ± 0.84 h) were similar (p = 0.07).
The renal clearance of morphine, 214 ± 36 m l.m hr1, 
differed significantly from that of morphine-3-glucuronide
124 ± 55 and morphine-6-glucuronide 139 + 46 m l.m kr1 
(p < 0.005). The renal clearance values of both glucu- 
ronides were similar (p = 0.59).
values and the bioa-Table 2 compares the AUCo 
vailability of the i.m. and i.v. administration of 20 mg of 
Vilan.
Discussion
Metabolism
When given intravenously nicomorphine is quick me-
100
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1
serum conc. ug/ml " 
renal excr. rate ug/min
20 mg Nicomorphine i.m.
M-3-gluc 63.3 %
1
M-6-gluc 7.6 %
M 11.1 %
..M-3-gluc 
t1/2 3.7 h
0.001
6MNM
\ t1/2 0.3 h
M
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t1/2 2.5 h
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Fig. 2 A combined figure of the serum concentration-time curves and 
the renal excretion-time curves for the same patient after an i.m. dose of 
2 0  mg nicomorphine.
In 6MNM glucuronidation is only possible at the
tabolized into the metabolites 6-mononicotinoyImorphine 3-position. However, no peak in the chromatogram is pres­
ent at a retention time that would fit the compound 
6MNM3G. Moreover, treatment of the serum and urine
samples with p-glucuronidase did not result in the increase 
of the concentration of 6MNM, while under these condi­
tions M3G and M6G completely were converted to M.
Morphine w as found in the serum 5 min after admin­
istration. Its elimination half-life was 1.38 ± 0.31 h. The 
rate of the morphine formation may not entirely be due to 
enzymatic reactions, but partly due to hydrolysis of 3MNM 
in serum.
Morphine is glucuronidated at the 3 and 6 position. 
These 2 glucuronide conjugates were present in plasma 
[Boerner et al. 1975, Garrett and Giirkan 1978, Garrett and 
the rate of absorption or formation. The whole process is Jackson 1979] and urine [Moore et al. 1984, Sftwe et al. 
governed by the rate of absorption of the parent drug 1985]. Morphine-3-glucuronide has been shown to be a
and morphine with a half-life of 1 min [Koopman-Kimenai 
et al. 1993]. This study shows that after intramuscular 
administration, nicomorphine was unexpectedly present in 
serum for a relatively long period. Its apparent elimination 
half-life is, therefore, governed by its rate of absorption and 
varied between 0.11 and 0.71 h.
The metab oh te 6MNM is present instantaneously in 
the serum while 3MNM could not be detected. The latter 
compound is unstable in solution (stock solution, blood) 
with rapid hydrolysis to morphine. The compound 6MNM 
is stable and can be measured. The elimination half-life of
6MNM is similar to that of nicomorphine: 0.39 ± 0.09 h (p 
= 0.29), indicating that its rate of elimination is higher than
nicomorphine. potent functional antagonist of morphine and morphine-6-
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glucuronide gives antinociception after intracerebro-ven­
tricular administration to rats [Gong et al. 1991, Smith et 
al. 1990]. The conjugate morphine-6-glucuronide con­
tributes to the analgesic effect [Osborne et al. 1990,1993, 
Shimomura et al. 1971]. No diglucuronide of morphine 
was found.
Bioavcdlability
After intravenous administration of 20 mg nicomor- 
phine to a comparable group of surgical patients the mean
AUCo-oo of the parent compound is 32 ± 10 |ig.h.l-1 (0.06
± 0.02 [xM.h.l"1) [Koopman-Kimenai et al. 1994]. After 
intramuscular administration of the same dose the mean
AUCo~oo of the parent compound is higher: 50 ± 20 (ig.h.l" 1
(0.10 ± 0.04 (LiM.h.l"1) (Table 1). This results in a bioavai­
lability of the parent compound of 156% (Table 2). This 
result can be explained by the fact that the apparent elimi­
nation half-life is governed by the absorption- rather than 
the eliminaton rate.
The bioavailability of this pharmaceutical formula­
tion can be expressed as AUCo-« (|xM.h.l-1) of the parent 
compound and all metabolites after Lm. administration in 
comparison to that after i.v. administration (at the same 
dose). After intravenous administration of 20 mg nicomor- 
phine the total sum of the area under the serum concentra­
tion time curve (AUCo-c of DNM + 6MNM + M + M3G
-I- M6G) is 4.78 |nM.h.H, [Koopman-Kimenai et al. 1994] 
which is in the same order of magnitude as after intra­
muscular administration of 20 mg nicomorphine: 4.07
pM.h.l“1, indicating a bioavailability of 85% (Table 2). If 
only the active compounds are taken into account, the 
AUCo-co of 6MNM + M + M6G after i.v. and i.m, after the 
same dose have to be compared. The AUCo-« (6MNM +
M + M6G) are identical: 0.91 joM.h.H (i.v.) and 0.86
(LtM.h.l-1 (i.m.), resulting in an i.m. bio availability of the 
active compounds of 95%. After i.v. administration the 
parent compound and 6MNM comprise only 2.9% of the 
total AUC. Because of the slower absorption of nicomor­
phine from the muscular- mass it is longer present in the 
blood and, therefore, nicomorphine and 6MNM comprised 
a larger part of the total AUCo^ after i.m. administration: 
5.5% (as was also indicated by the bioavailability of the 
parent compound of 156%) [Koopman-Kimenai et al. 
1994], The assessment of bioavailability in surgical pa­
tients is only feasable using a parallel study design, ap­
proximating the absolute bioavailability obtained from a 
cross-over design.
Renal clearance
In urine only morphine and its conjugates were pres­
ent. The renal clearance (CLr) of all metabolites is listed 
in Table 1. There are large inter-individual differences, but
it is remarkable that the renal clearance of morphine (mean 
214 ml.min”1) is higher than that of both glucuronides 
(mean 132 ml.min"'1). This is explained by the different 
excretion mechanisms: morphine is cleared via the organic 
cation transport system, while the glucuronides are cleared 
by glomerular filtration and tubular reabsorption [Greven 
1981]. These results are in perfect accordance with our 
results after i.v. administration: 200 (M) and 115 ml.min-1 
(M3G, M6G), respectively. As van Crugten et al. [1991] 
described, it is an unusual phenomenon that glucuronide 
metabolites, which are larger and less lipophilic than mor­
phine, undergo net tubular reabsorption. However, Carrupt 
et al. [1991] described that M6G and to a lesser extent M3G 
are far more lipophilic than predicted and, in fact, are not 
much less lipophilic than morphine.
Clinical implications
The prodrug nicomorphine is biotransformed into 3 
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